A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Latest Information Update: 24 Mar 2026
At a glance
- Drugs Allantoin (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Cambridge
Most Recent Events
- 24 Mar 2026 New trial record